NASDAQ · Biotechnology

KLRS (KLRS) Stock

$3.40 +1.80% NASDAQ: KLRS Healthcare

Valuation

MetricValue
Price$3.40
Market Cap$63.59M
P/E Ratio-2.86
P/B Ratio1.52
P/S Ratio0.00
EPS (TTM)$-1.52
52-Week High$11.88
52-Week Low$2.14
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-66.60%
ROA-27.97%
ROCE-58.23%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio11.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-170.0M$-14.0M$-13.0M$-55.0M$-46.0M
Net Profit$-172.0M$-15.0M$-15.0M$-59.0M$-43.0M
EPS$-63.00$-50.62$-42.09$-11.73$-2.85
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$287.0M$4.0M$3.0M$119.0M$122.0M
Total Liabilities$61.0M$34.0M$48.0M$5.0M$43.0M
Cash$202.0M$3.0M$3.0M$118.0M$98.0M
Borrowings$30.0M$3.0M$0$0$1.0M

Latest News

Kalaris Therapeutics (KLRS) Appoints Laurie Keating to Board Insider Monkey · Jul 14, 2026 Kalaris Appoints Laurie Keating to Board of Directors GlobeNewswire · Jul 6, 2026 Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling GlobeNewswire · Jun 23, 2026 TD Cowen Initiates Kalaris Therapeutics at Buy MT Newswires · Jun 15, 2026 Kalaris to Present at Clinical Trials at the Summit 2026 GlobeNewswire · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-106.0M$-10.0M$-14.0M$-68.0M$-43.0M
Investing Cash Flow$186.0M$0$0$95.0M$-20.0M
Financing Cash Flow$0$0$2.0M$0$102.0M
Net Cash Flow$79.0M$3.0M$0$28.0M$-20.0M
Free Cash Flow$-106.0M$-10.0M$-14.0M$-68.0M$-43.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-10.97
EV / EBITDA—
FCF Yield-57.55%
Quick Ratio12.14
Interest Coverage-46.00
Return 1Y94.58%
Return 3Y-94.20%
Return 5Y-98.85%

Ownership

Insiders Held8.81%
Institutions Held77.88%
Institutions Float Held85.40%
Institutional HolderSharesReport Date
Samsara BioCapital, LLC12,948,0812026-03-31
RTW Investments LP1,300,0002026-03-31
Paradigm Biocapital Advisors LP700,0002026-03-31
Alyeska Investment Group, L.p.572,6872026-03-31
Siren, L.L.C.435,7982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTV $11.27 -2.68% -2.29 $278.56M 0.00%
CNTB $2.07 -1.67% -2.31 $130.02M 0.00%
CNTX $0.62 +4.47% -6.84 $56.69M 0.00%
IFRX $1.84 +6.98% -4.16 $132.91M 0.00%
IMA $5.69 +1.07% -1.49 $64.18M 0.00%

About KLRS

KLRS is led by CEO Andrew Oxtoby, employs 14 people, headquartered in US, publicly traded since 2020.

KLRS stock trades at $3.40 with a market capitalization of $63.59M. The stock is valued at a price-to-earnings (P/E) ratio of -2.86, price-to-book of 1.52, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.14 and $11.88, and currently trades 71.4% below its 52-week high.

On profitability, KLRS generates a return on equity (ROE) of -66.60%, return on capital employed of -58.23%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides